CAS: 1809068-70-9
Brand | Product data | Purity | Price range | Estimated delivery |
---|---|---|---|---|
N-[(1S,2S,3R)-3-(5,6-Dihydrobenzo[b][1]benzazepin-11-yl)-2-hydroxycyclohexyl]-4-(trifluoromethoxy)benzenesulfonamide REF: 3D-JXC06870CAS: 1809068-70-9 | Min. 95% | 453.00 €~4,405.00 € | Fri 27 Dec 24 | |
SMAP-2 REF: TM-T12934CAS: 1809068-70-9 | 98% | To inquire | Fri 03 Jan 25 |
N-[(1S,2S,3R)-3-(5,6-Dihydrobenzo[b][1]benzazepin-11-yl)-2-hydroxycyclohexyl]-4-(trifluoromethoxy)benzenesulfonamide
CAS:1809068-70-9
Please enquire for more information about N-[(1S,2S,3R)-3-(5,6-Dihydrobenzo[b][1]benzazepin-11-yl)-2-hydroxycyclohexyl]-4-(trifluoromethoxy)benzenesulfonamide including the price, delivery time and more detailed …
Formula:
C27H27F3N2O4S
Purity:
Min. 95%
Molecular weight:
532.6 g/mol
Ref: 3D-JXC06870
1mg | 453.00 € | ||
2mg | 711.00 € | ||
5mg | 1,276.00 € | ||
10mg | 1,855.00 € | ||
25mg | 4,405.00 € |
Estimated delivery in United States, on Friday 27 Dec 2024
SMAP-2
CAS:1809068-70-9
SMAP-2: oral PP2A activator, targets Aα subunit, halts KRAS-mutant lung cancer growth.
Formula:
C27H27F3N2O4S
Purity:
98%
Color and Shape:
Solid
Molecular weight:
532.57
Ref: TM-T12934
25mg | 1,410.00 € | ||
50mg | 1,845.00 € | ||
100mg | 2,329.00 € |
Estimated delivery in United States, on Friday 3 Jan 2025